;PMID: 11932209
;source_file_1895.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..158] = [t:46..158]
;2)section:[e:162..212] = [t:162..212]
;3)section:[e:216..365] = [t:216..365]
;4)sentence:[e:369..538] = [t:369..538]
;5)sentence:[e:539..683] = [t:539..683]
;6)sentence:[e:684..821] = [t:684..821]
;7)sentence:[e:822..906] = [t:822..906]
;8)sentence:[e:908..1056] = [t:908..1056]
;9)sentence:[e:1057..1340] = [t:1057..1340]
;10)sentence:[e:1341..1491] = [t:1341..1491]
;11)sentence:[e:1492..1588] = [t:1492..1588]
;12)sentence:[e:1589..1676] = [t:1589..1676]
;13)sentence:[e:1677..1879] = [t:1677..1879]
;14)sentence:[e:1880..2001] = [t:1880..2001]
;15)sentence:[e:2002..2163] = [t:2002..2163]
;16)sentence:[e:2164..2371] = [t:2164..2371]
;17)sentence:[e:2372..2559] = [t:2372..2559]
;18)sentence:[e:2560..2792] = [t:2560..2792]
;19)sentence:[e:2793..2920] = [t:2793..2920]
;20)sentence:[e:2922..3022] = [t:2922..3022]
;21)section:[e:3026..3071] = [t:3026..3071]

;section 0 Span:0..40
;J Mol Endocrinol. 2002 Apr;28(2):125-35.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..5] Mol) (NNP:[6..16] Endocrinol) (.:[16..17] .)
        ('':[18..22] 2002) (CC:[23..30] Apr;28-LRB-) (CD:[30..31] 2)
        (-RRB-:[31..32] -RRB-) (::[32..33] :) (CD:[33..39] 125-35)
        (.:[39..40] .)))

;sentence 1 Span:46..158
;Differential regulation of aldosterone synthase and 11beta-hydroxylase 
;transcription by steroidogenic factor-1.
;[73..93]:cyp450:"aldosterone synthase"
;[98..116]:cyp450:"11beta-hydroxylase"
;[135..157]:substance:"steroidogenic factor-1"
(SENT
  (NP
    (NP (JJ:[46..58] Differential) (NN:[59..69] regulation))
    (PP (IN:[70..72] of)
      (NP
        (NP (NN:[73..84] aldosterone) (NN:[85..93] synthase))
        (CC:[94..97] and)
        (NP (NN:[98..116] 11beta-hydroxylase) (NN:[118..131] transcription))))
    (PP (IN:[132..134] by)
      (NP (JJ:[135..148] steroidogenic) (NN:[149..157] factor-1)))
    (.:[157..158] .)))

;section 2 Span:162..212
;Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE.
(SEC
  (FRAG (NNP:[162..169] Bassett) (NN:[170..172] MH) (,:[172..173] ,)
        (NNP:[174..179] Zhang) (NNP:[180..181] Y) (,:[181..182] ,)
        (NNP:[183..188] Clyne) (NNP:[189..190] C) (,:[190..191] ,)
        (JJ:[192..197] White) (NN:[198..200] PC) (,:[200..201] ,)
        (NNP:[202..208] Rainey) (NNP:[209..212] WE.)))

;section 3 Span:216..365
;Department of Obstetrics and Gynecology, University of Texas Southwestern 
;Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9032, USA.
(SEC
  (FRAG (NNP:[216..226] Department) (IN:[227..229] of)
        (NNP:[230..240] Obstetrics) (CC:[241..244] and)
        (NNP:[245..255] Gynecology) (,:[255..256] ,) (NNP:[257..267] University)
        (IN:[268..270] of) (NNP:[271..276] Texas) (NNP:[277..289] Southwestern)
        (NNP:[291..298] Medical) (NNP:[299..305] Center) (,:[305..306] ,)
        (CD:[307..311] 5323) (NNP:[312..317] Harry) (NNP:[318..323] Hines)
        (NNP:[324..333] Boulevard) (,:[333..334] ,) (NNP:[335..341] Dallas)
        (,:[341..342] ,) (NNP:[343..348] Texas) (CD:[349..354] 75390)
        (HYPH:[354..355] -) (CD:[355..359] 9032) (,:[359..360] ,)
        (NNP:[361..364] USA) (.:[364..365] .)))

;sentence 4 Span:369..538
;11beta-Hydroxylase (hCYP11B1) and aldosterone synthase (hCYP11B2) are closely
; related isozymes with distinct roles in cortisol and aldosterone production 
;respectively.
;[369..387]:cyp450:"11beta-Hydroxylase"
;[389..397]:cyp450:"hCYP11B1"
;[403..423]:cyp450:"aldosterone synthase"
;[425..433]:cyp450:"hCYP11B2"
;[456..464]:cyp450:"isozymes"
;[488..496]:substance:"cortisol"
;[501..512]:substance:"aldosterone"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[369..387] 11beta-Hydroxylase))
        (NP (-LRB-:[388..389] -LRB-) (NN:[389..397] hCYP11B1)
            (-RRB-:[397..398] -RRB-)))
      (CC:[399..402] and)
      (NP
        (NP (NN:[403..414] aldosterone) (NN:[415..423] synthase))
        (NP (-LRB-:[424..425] -LRB-) (NN:[425..433] hCYP11B2)
            (-RRB-:[433..434] -RRB-))))
    (VP (VBP:[435..438] are)
      (NP-PRD
        (NP
          (ADJP (RB:[439..446] closely) (VBN:[448..455] related))
          (NNS:[456..464] isozymes))
        (PP (IN:[465..469] with)
          (NP
            (NP (JJ:[470..478] distinct) (NNS:[479..484] roles))
            (PP-LOC (IN:[485..487] in)
              (NP
                (NP (NN:[488..496] cortisol)
                  (NML-1 (-NONE-:[496..496] *P*)))
                (CC:[497..500] and)
                (NP (NN:[501..512] aldosterone)
                  (NML-1 (NN:[513..523] production)))
                (ADVP (RB:[525..537] respectively))))))))
    (.:[537..538] .)))

;sentence 5 Span:539..683
;Aldosterone synthase catalyzes the final step in aldosterone  biosynthesis
;and is expressed only in the zona glomerulosa of the normal  adrenal.
;[539..559]:cyp450:"Aldosterone synthase"
;[588..599]:substance:"aldosterone"
(SENT
  (S
    (NP-SBJ-1 (NN:[539..550] Aldosterone) (NN:[551..559] synthase))
    (VP
      (VP (VBZ:[560..569] catalyzes)
        (NP
          (NP (DT:[570..573] the) (JJ:[574..579] final) (NN:[580..584] step))
          (PP (IN:[585..587] in)
            (NP (NN:[588..599] aldosterone) (NN:[601..613] biosynthesis)))))
      (CC:[614..617] and)
      (VP (VBZ:[618..620] is)
        (VP (VBN:[621..630] expressed)
          (NP-1 (-NONE-:[630..630] *))
          (PP-LOC
            (ADVP (RB:[631..635] only))
            (IN:[636..638] in)
            (NP
              (NP (DT:[639..642] the) (NN:[643..647] zona)
                  (NN:[648..659] glomerulosa))
              (PP (IN:[660..662] of)
                (NP (DT:[663..666] the) (JJ:[667..673] normal)
                    (NN:[675..682] adrenal))))))))
    (.:[682..683] .)))

;sentence 6 Span:684..821
;11beta-Hydroxylase catalyzes the final reaction in the production of 
;cortisol and is expressed at higher levels in the zona fasciculata.
;[684..702]:cyp450:"11beta-Hydroxylase"
;[754..762]:substance:"cortisol"
(SENT
  (S
    (NP-SBJ-1 (NN:[684..702] 11beta-Hydroxylase))
    (VP
      (VP (VBZ:[703..712] catalyzes)
        (NP
          (NP (DT:[713..716] the) (JJ:[717..722] final) (NN:[723..731] reaction))
          (PP (IN:[732..734] in)
            (NP
              (NP (DT:[735..738] the) (NN:[739..749] production))
              (PP (IN:[750..752] of)
                (NP (NN:[754..762] cortisol)))))))
      (CC:[763..766] and)
      (VP (VBZ:[767..769] is)
        (VP (VBN:[770..779] expressed)
          (NP-1 (-NONE-:[779..779] *))
          (PP (IN:[780..782] at)
            (NP (JJR:[783..789] higher) (NNS:[790..796] levels)))
          (PP-LOC (IN:[797..799] in)
            (NP (DT:[800..803] the) (NN:[804..808] zona)
                (NN:[809..820] fasciculata))))))
    (.:[820..821] .)))

;sentence 7 Span:822..906
;The  mechanisms causing differential expression of these genes are not well
;defined.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[822..825] The) (NNS:[827..837] mechanisms))
      (VP (VBG:[838..845] causing)
        (NP
          (NP (JJ:[846..858] differential) (NN:[859..869] expression))
          (PP (IN:[870..872] of)
            (NP (DT:[873..878] these) (NNS:[879..884] genes))))))
    (VP (VBP:[885..888] are) (RB:[889..892] not)
      (ADVP (RB:[893..897] well))
      (VP (VBN:[898..905] defined)
        (NP-1 (-NONE-:[905..905] *))))
    (.:[905..906] .)))

;sentence 8 Span:908..1056
;Herein, we demonstrate contrasting roles for the orphan receptor
;steroidogenic  factor-1 (SF-1) in the regulation of human (h) CYP11B1 and
;hCYP11B2.
;[964..972]:substance:"receptor"
;[973..996]:substance:"steroidogenic  factor-1"
;[998..1002]:substance:"SF-1"
;[1025..1042]:cyp450:"human (h) CYP11B1"
;[1047..1055]:cyp450:"hCYP11B2"
(SENT
  (S
    (ADVP-LOC (RB:[908..914] Herein))
    (,:[914..915] ,)
    (NP-SBJ (PRP:[916..918] we))
    (VP (VBP:[919..930] demonstrate)
      (NP
        (NP (VBG:[931..942] contrasting) (NNS:[943..948] roles))
        (PP (IN:[949..952] for)
          (NP
            (NP (DT:[953..956] the) (NN:[957..963] orphan)
                (NN:[964..972] receptor))
            (NP
              (NP (JJ:[973..986] steroidogenic) (NN:[988..996] factor-1))
              (NP (-LRB-:[997..998] -LRB-) (NN:[998..1002] SF-1)
                  (-RRB-:[1002..1003] -RRB-)))))
        (PP (IN:[1004..1006] in)
          (NP
            (NP (DT:[1007..1010] the) (NN:[1011..1021] regulation))
            (PP (IN:[1022..1024] of)
              (NP
                (NP
                  (NML
                    (NML (JJ:[1025..1030] human))
                    (NML (-LRB-:[1031..1032] -LRB-) (JJ:[1032..1033] h)
                         (-RRB-:[1033..1034] -RRB-)))
                  (NN:[1035..1042] CYP11B1))
                (CC:[1043..1046] and)
                (NP (NN:[1047..1055] hCYP11B2))))))))
    (.:[1055..1056] .)))

;sentence 9 Span:1057..1340
;Human  NCI-H295R (H295R) or mouse Y-1 cells were transiently transfected with
; luciferase reporter constructs containing 5'-flanking regions of hCYP11B1, 
;hCYP11B2, human 17alpha-hydroxylase (hCYP17), human cholesterol side-chain 
;cleavage (hCYP11A1) or mouse (m) cyp11b2 (mcyp11b2).
;[1136..1146]:substance:"luciferase"
;[1147..1155]:substance:"reporter"
;[1201..1209]:cyp450:"hCYP11B1"
;[1212..1220]:cyp450:"hCYP11B2"
;[1222..1247]:cyp450:"human 17alpha-hydroxylase"
;[1249..1255]:cyp450:"hCYP17"
;[1258..1296]:cyp450:"human cholesterol side-chain  cleavage"
;[1298..1306]:cyp450:"hCYP11A1"
;[1311..1328]:cyp450:"mouse (m) cyp11b2"
;[1330..1338]:cyp450:"mcyp11b2"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NML
          (NML (JJ:[1057..1062] Human) (NN:[1064..1073] NCI-H295R))
          (NML (-LRB-:[1074..1075] -LRB-) (NN:[1075..1080] H295R)
               (-RRB-:[1080..1081] -RRB-)))
        (NML-1 (-NONE-:[1081..1081] *P*)))
      (CC:[1082..1084] or)
      (NP (NN:[1085..1090] mouse) (NN:[1091..1094] Y-1)
        (NML-1 (NNS:[1095..1100] cells))))
    (VP (VBD:[1101..1105] were)
      (ADVP-MNR (RB:[1106..1117] transiently))
      (VP (VBN:[1118..1129] transfected)
        (NP-2 (-NONE-:[1129..1129] *))
        (PP (IN:[1130..1134] with)
          (NP
            (NP (NN:[1136..1146] luciferase) (NN:[1147..1155] reporter)
                (NNS:[1156..1166] constructs))
            (VP (VBG:[1167..1177] containing)
              (NP
                (NP
                  (NML
                    (NML (CD:[1178..1179] 5) (SYM:[1179..1180] '))
                    (HYPH:[1180..1181] -) (NN:[1181..1189] flanking))
                  (NNS:[1190..1197] regions))
                (PP (IN:[1198..1200] of)
                  (NP
                    (NP (NN:[1201..1209] hCYP11B1))
                    (,:[1209..1210] ,)
                    (NP (NN:[1212..1220] hCYP11B2))
                    (,:[1220..1221] ,)
                    (NP
                      (NP (JJ:[1222..1227] human)
                          (NN:[1228..1247] 17alpha-hydroxylase))
                      (NP (-LRB-:[1248..1249] -LRB-) (NN:[1249..1255] hCYP17)
                          (-RRB-:[1255..1256] -RRB-)))
                    (,:[1256..1257] ,)
                    (NP
                      (NP (JJ:[1258..1263] human) (NN:[1264..1275] cholesterol)
                        (NML (NN:[1276..1280] side) (HYPH:[1280..1281] -)
                             (NN:[1281..1286] chain))
                        (NN:[1288..1296] cleavage))
                      (NP (-LRB-:[1297..1298] -LRB-) (NN:[1298..1306] hCYP11A1)
                          (-RRB-:[1306..1307] -RRB-)))
                    (CC:[1308..1310] or)
                    (NP
                      (NP
                        (NML
                          (NML (NN:[1311..1316] mouse))
                          (NML (-LRB-:[1317..1318] -LRB-) (NN:[1318..1319] m)
                               (-RRB-:[1319..1320] -RRB-)))
                        (NN:[1321..1328] cyp11b2))
                      (NP (-LRB-:[1329..1330] -LRB-) (NN:[1330..1338] mcyp11b2)
                          (-RRB-:[1338..1339] -RRB-)))))))))))
    (.:[1339..1340] .)))

;sentence 10 Span:1341..1491
;Co-transfection of vectors  encoding SF-1 increased expression of hCYP11B1,
;hCYP11A1 and hCYP17 constructs,  but inhibited hCYP11B2 reporter activity.
;[1378..1382]:substance:"SF-1"
;[1407..1415]:cyp450:"hCYP11B1"
;[1417..1425]:cyp450:"hCYP11A1"
;[1430..1436]:cyp450:"hCYP17"
;[1464..1472]:cyp450:"hCYP11B2"
;[1473..1481]:substance:"reporter"
(SENT
  (S
    (NP-SBJ
      (NP (AFX:[1341..1343] Co) (HYPH:[1343..1344] -)
          (NN:[1344..1356] transfection))
      (PP (IN:[1357..1359] of)
        (NP
          (NP (NNS:[1360..1367] vectors))
          (VP (VBG:[1369..1377] encoding)
            (NP (NN:[1378..1382] SF-1))))))
    (VP
      (VP (VBD:[1383..1392] increased)
        (NP
          (NP (NN:[1393..1403] expression))
          (PP (IN:[1404..1406] of)
            (NP
              (NP (NN:[1407..1415] hCYP11B1)
                (NML-1 (-NONE-:[1415..1415] *P*)))
              (,:[1415..1416] ,)
              (NP (NN:[1417..1425] hCYP11A1)
                (NML-1 (-NONE-:[1425..1425] *P*)))
              (CC:[1426..1429] and)
              (NP (NN:[1430..1436] hCYP17)
                (NML-1 (NNS:[1437..1447] constructs)))))))
      (,:[1447..1448] ,) (CC:[1450..1453] but)
      (VP (VBD:[1454..1463] inhibited)
        (NP (NN:[1464..1472] hCYP11B2) (NN:[1473..1481] reporter)
            (NN:[1482..1490] activity))))
    (.:[1490..1491] .)))

;sentence 11 Span:1492..1588
;Murine, bovine and human SF-1 were  unable to increase transcription of
;hCYP11B2 in H295R cells.
;[1517..1521]:substance:"SF-1"
;[1564..1572]:cyp450:"hCYP11B2"
(SENT
  (S
    (NP-SBJ-2
      (NP (JJ:[1492..1498] Murine)
        (NML-1 (-NONE-:[1498..1498] *P*)))
      (,:[1498..1499] ,)
      (NP (JJ:[1500..1506] bovine)
        (NML-1 (-NONE-:[1506..1506] *P*)))
      (CC:[1507..1510] and)
      (NP (JJ:[1511..1516] human)
        (NML-1 (NN:[1517..1521] SF-1))))
    (VP (VBD:[1522..1526] were)
      (ADJP-PRD (JJ:[1528..1534] unable)
        (S
          (NP-SBJ-2 (-NONE-:[1534..1534] *))
          (VP (TO:[1535..1537] to)
            (VP (VB:[1538..1546] increase)
              (NP
                (NP (NN:[1547..1560] transcription))
                (PP (IN:[1561..1563] of)
                  (NP (NN:[1564..1572] hCYP11B2))))
              (PP-LOC (IN:[1573..1575] in)
                (NP (NN:[1576..1581] H295R) (NNS:[1582..1587] cells))))))))
    (.:[1587..1588] .)))

;sentence 12 Span:1589..1676
;Both hCYP11B2 and  mcyp11b2 promoter constructs were inhibited similarly by
;human SF-1.
;[1594..1602]:cyp450:"hCYP11B2"
;[1608..1616]:cyp450:"mcyp11b2"
;[1617..1625]:substance:"promoter"
;[1671..1675]:substance:"SF-1"
(SENT
  (S
    (NP-SBJ-2 (CC:[1589..1593] Both)
      (NP (NN:[1594..1602] hCYP11B2)
        (NML-1 (-NONE-:[1602..1602] *P*)))
      (CC:[1603..1606] and)
      (NP (NN:[1608..1616] mcyp11b2)
        (NML-1 (NN:[1617..1625] promoter) (NNS:[1626..1636] constructs))))
    (VP (VBD:[1637..1641] were)
      (VP (VBN:[1642..1651] inhibited)
        (NP-2 (-NONE-:[1651..1651] *))
        (ADVP-MNR (RB:[1652..1661] similarly))
        (PP (IN:[1662..1664] by)
          (NP-LGS (JJ:[1665..1670] human) (NN:[1671..1675] SF-1)))))
    (.:[1675..1676] .)))

;sentence 13 Span:1677..1879
;In mouse  Y-1 cells, reporter expression of hCYP11B2 and mcyp11b2 was very
;low compared  with hCYP11B1 constructs, suggesting that this adrenal cell
;model may not be  appropriate for studies of CYP11B2.
;[1698..1706]:substance:"reporter"
;[1721..1729]:cyp450:"hCYP11B2"
;[1734..1742]:cyp450:"mcyp11b2"
;[1771..1779]:cyp450:"hCYP11B1"
;[1871..1878]:cyp450:"CYP11B2"
(SENT
  (S
    (PP-LOC (IN:[1677..1679] In)
      (NP (NN:[1680..1685] mouse) (NN:[1687..1690] Y-1) (NNS:[1691..1696] cells)))
    (,:[1696..1697] ,)
    (NP-SBJ
      (NP (NN:[1698..1706] reporter) (NN:[1707..1717] expression))
      (PP (IN:[1718..1720] of)
        (NP (NN:[1721..1729] hCYP11B2) (CC:[1730..1733] and)
            (NN:[1734..1742] mcyp11b2))))
    (VP (VBD:[1743..1746] was)
      (ADJP-PRD (RB:[1747..1751] very) (JJ:[1752..1755] low))
      (S-ADV
        (NP-SBJ-1 (-NONE-:[1755..1755] *))
        (VP (VBN:[1756..1764] compared)
          (NP-1 (-NONE-:[1764..1764] *))
          (PP-CLR (IN:[1766..1770] with)
            (NP (NN:[1771..1779] hCYP11B1) (NNS:[1780..1790] constructs)))))
      (,:[1790..1791] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1791..1791] *))
        (VP (VBG:[1792..1802] suggesting)
          (SBAR (IN:[1803..1807] that)
            (S
              (NP-SBJ (DT:[1808..1812] this) (JJ:[1813..1820] adrenal)
                      (NN:[1821..1825] cell) (NN:[1826..1831] model))
              (VP (MD:[1832..1835] may) (RB:[1836..1839] not)
                (VP (VB:[1840..1842] be)
                  (ADJP-PRD (JJ:[1844..1855] appropriate)
                    (PP (IN:[1856..1859] for)
                      (NP
                        (NP (NNS:[1860..1867] studies))
                        (PP (IN:[1868..1870] of)
                          (NP (NN:[1871..1878] CYP11B2)))))))))))))
    (.:[1878..1879] .)))

;sentence 14 Span:1880..2001
;Electrophoretic mobility shift assay  demonstrated that SF-1 interacted with
;an element from both hCYP11B1 and  hCYP11B2.
;[1936..1940]:substance:"SF-1"
;[1978..1986]:cyp450:"hCYP11B1"
;[1992..2000]:cyp450:"hCYP11B2"
(SENT
  (S
    (NP-SBJ
      (NML (JJ:[1880..1895] Electrophoretic) (NN:[1896..1904] mobility)
           (NN:[1905..1910] shift))
      (NN:[1911..1916] assay))
    (VP (VBD:[1918..1930] demonstrated)
      (SBAR (IN:[1931..1935] that)
        (S
          (NP-SBJ (NN:[1936..1940] SF-1))
          (VP (VBD:[1941..1951] interacted)
            (PP-CLR (IN:[1952..1956] with)
              (NP
                (NP (DT:[1957..1959] an) (NN:[1960..1967] element))
                (PP (IN:[1968..1972] from)
                  (NP (CC:[1973..1977] both) (NN:[1978..1986] hCYP11B1)
                      (CC:[1987..1990] and) (NN:[1992..2000] hCYP11B2)))))))))
    (.:[2000..2001] .)))

;sentence 15 Span:2002..2163
;However, mutation of this element, termed Ad4, did not prevent agonist 
;stimulation of hCYP11B2 by angiotensin II or forskolin but blocked activity
;of  hCYP11B1.
;[2065..2072]:substance:"agonist"
;[2089..2097]:cyp450:"hCYP11B2"
;[2101..2115]:substance:"angiotensin II"
;[2119..2128]:substance:"forskolin"
;[2154..2162]:cyp450:"hCYP11B1"
(SENT
  (S
    (ADVP (RB:[2002..2009] However))
    (,:[2009..2010] ,)
    (NP-SBJ
      (NP
        (NP (NN:[2011..2019] mutation))
        (PP (IN:[2020..2022] of)
          (NP (DT:[2023..2027] this) (NN:[2028..2035] element))))
      (,:[2035..2036] ,)
      (VP (VBN:[2037..2043] termed)
        (S
          (NP-SBJ (-NONE-:[2043..2043] *))
          (NP-PRD (NN:[2044..2047] Ad4)))))
    (,:[2047..2048] ,)
    (VP
      (VP (VBD:[2049..2052] did) (RB:[2053..2056] not)
        (VP (VB:[2057..2064] prevent)
          (NP
            (NP (NN:[2065..2072] agonist) (NN:[2074..2085] stimulation))
            (PP (IN:[2086..2088] of)
              (NP (NN:[2089..2097] hCYP11B2)))
            (PP (IN:[2098..2100] by)
              (NP
                (NP (NN:[2101..2112] angiotensin) (CD:[2113..2115] II))
                (CC:[2116..2118] or)
                (NP (NN:[2119..2128] forskolin)))))))
      (CC:[2129..2132] but)
      (VP (VBD:[2133..2140] blocked)
        (NP
          (NP (NN:[2141..2149] activity))
          (PP (IN:[2150..2152] of)
            (NP (NN:[2154..2162] hCYP11B1))))))
    (.:[2162..2163] .)))

;sentence 16 Span:2164..2371
;In some, but not all, reports of genetic linkage analysis, a naturally 
;occurring single nucleotide polymorphism within the Ad4 element of hCYP11B2 
;(-344C/T) has been associated with cardiovascular disease.
;[2303..2311]:cyp450:"hCYP11B2"
(SENT
  (S
    (PP-LOC (IN:[2164..2166] In)
      (NP
        (NP (DT:[2167..2171] some)
          (NP-2 (-NONE-:[2171..2171] *P*)))
        (,:[2171..2172] ,)
        (CONJP (CC:[2173..2176] but) (RB:[2177..2180] not))
        (NP (DT:[2181..2184] all) (,:[2184..2185] ,)
          (NP-2
            (NP (NNS:[2186..2193] reports))
            (PP (IN:[2194..2196] of)
              (NP
                (NML (JJ:[2197..2204] genetic) (NN:[2205..2212] linkage))
                (NN:[2213..2221] analysis)))))))
    (,:[2221..2222] ,)
    (NP-SBJ-1
      (NP (DT:[2223..2224] a)
        (ADJP (RB:[2225..2234] naturally) (VBG:[2236..2245] occurring))
        (NML (JJ:[2246..2252] single) (NN:[2253..2263] nucleotide))
        (NN:[2264..2276] polymorphism))
      (PP-LOC (IN:[2277..2283] within)
        (NP
          (NP (DT:[2284..2287] the) (NN:[2288..2291] Ad4)
              (NN:[2292..2299] element))
          (PP (IN:[2300..2302] of)
            (NP
              (NP (NN:[2303..2311] hCYP11B2))
              (PRN (-LRB-:[2313..2314] -LRB-)
                (NP
                  (NML (SYM:[2314..2315] -) (CD:[2315..2318] 344))
                  (NN:[2318..2319] C))
                (PP (SYM:[2319..2320] /)
                  (NP (NN:[2320..2321] T)))
                (-RRB-:[2321..2322] -RRB-)))))))
    (VP (VBZ:[2323..2326] has)
      (VP (VBN:[2327..2331] been)
        (VP (VBN:[2332..2342] associated)
          (NP-1 (-NONE-:[2342..2342] *))
          (PP-CLR (IN:[2343..2347] with)
            (NP (JJ:[2348..2362] cardiovascular) (NN:[2363..2370] disease))))))
    (.:[2370..2371] .)))

;sentence 17 Span:2372..2559
;Herein, we have  demonstrated that this polymorphism influenced binding of
;SF-1 in  electrophoretic mobility shift assays, with the C allele binding
;SF-1 more  strongly than the T allele.
;[2447..2451]:substance:"SF-1"
;[2521..2525]:substance:"SF-1"
(SENT
  (S
    (ADVP-LOC (RB:[2372..2378] Herein))
    (,:[2378..2379] ,)
    (NP-SBJ (PRP:[2380..2382] we))
    (VP (VBP:[2383..2387] have)
      (VP (VBN:[2389..2401] demonstrated)
        (SBAR (IN:[2402..2406] that)
          (S
            (NP-SBJ (DT:[2407..2411] this) (NN:[2412..2424] polymorphism))
            (VP (VBD:[2425..2435] influenced)
              (NP
                (NP (NN:[2436..2443] binding))
                (PP (IN:[2444..2446] of)
                  (NP (NN:[2447..2451] SF-1))))
              (PP (IN:[2452..2454] in)
                (NP
                  (NML (JJ:[2456..2471] electrophoretic)
                       (NN:[2472..2480] mobility) (NN:[2481..2486] shift))
                  (NNS:[2487..2493] assays)))
              (,:[2493..2494] ,)
              (PP (IN:[2495..2499] with)
                (S-NOM
                  (NP-SBJ (DT:[2500..2503] the) (NN:[2504..2505] C)
                          (NN:[2506..2512] allele))
                  (VP (VBG:[2513..2520] binding)
                    (NP (NN:[2521..2525] SF-1))
                    (ADVP-MNR
                      (ADVP (RBR:[2526..2530] more) (RB:[2532..2540] strongly))
                      (PP (IN:[2541..2545] than)
                        (NP (DT:[2546..2549] the) (NN:[2550..2551] T)
                            (NN:[2552..2558] allele))))))))))))
    (.:[2558..2559] .)))

;sentence 18 Span:2560..2792
;However, when hCYP11B2 constructs containing these  alleles were transfected
;into H295R cells, there was no difference in  agonist-stimulated expression
;or the response of either reporter construct to  co-expression with human
;SF-1.
;[2574..2582]:cyp450:"hCYP11B2"
;[2683..2690]:substance:"agonist"
;[2739..2747]:substance:"reporter"
;[2787..2791]:substance:"SF-1"
(SENT
  (S
    (ADVP (RB:[2560..2567] However))
    (,:[2567..2568] ,)
    (SBAR-ADV
      (WHADVP-3 (WRB:[2569..2573] when))
      (S
        (NP-SBJ-1
          (NP (NN:[2574..2582] hCYP11B2) (NNS:[2583..2593] constructs))
          (VP (VBG:[2594..2604] containing)
            (NP (DT:[2605..2610] these) (NNS:[2612..2619] alleles))))
        (VP (VBD:[2620..2624] were)
          (VP (VBN:[2625..2636] transfected)
            (NP-1 (-NONE-:[2636..2636] *))
            (PP-LOC (IN:[2637..2641] into)
              (NP (NN:[2642..2647] H295R) (NNS:[2648..2653] cells)))
            (ADVP-TMP-3 (-NONE-:[2653..2653] *T*))))))
    (,:[2653..2654] ,)
    (NP-SBJ (EX:[2655..2660] there))
    (VP (VBD:[2661..2664] was)
      (NP-PRD
        (NP (DT:[2665..2667] no) (NN:[2668..2678] difference))
        (PP (IN:[2679..2681] in)
          (NP
            (NP
              (ADJP (NN:[2683..2690] agonist) (HYPH:[2690..2691] -)
                    (VBN:[2691..2701] stimulated))
              (NN:[2702..2712] expression))
            (CC:[2713..2715] or)
            (NP
              (NP (DT:[2716..2719] the) (NN:[2720..2728] response))
              (PP (IN:[2729..2731] of)
                (NP (DT:[2732..2738] either) (NN:[2739..2747] reporter)
                    (NN:[2748..2757] construct)))
              (PP (TO:[2758..2760] to)
                (NP
                  (NP (AFX:[2762..2764] co) (HYPH:[2764..2765] -)
                      (NN:[2765..2775] expression))
                  (PP (IN:[2776..2780] with)
                    (NP (JJ:[2781..2786] human) (NN:[2787..2791] SF-1))))))))))
    (.:[2791..2792] .)))

;sentence 19 Span:2793..2920
;Taken together, these data suggest that SF-1 and  the Ad4 element are not
;major regulators of adrenal hCYP11B2 gene expression.
;[2833..2837]:substance:"SF-1"
;[2873..2883]:substance:"regulators"
;[2895..2903]:cyp450:"hCYP11B2"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[2793..2793] *))
      (VP (VBN:[2793..2798] Taken)
        (ADVP (RB:[2799..2807] together))))
    (,:[2807..2808] ,)
    (NP-SBJ (DT:[2809..2814] these) (NNS:[2815..2819] data))
    (VP (VBP:[2820..2827] suggest)
      (SBAR (IN:[2828..2832] that)
        (S
          (NP-SBJ
            (NP (NN:[2833..2837] SF-1))
            (CC:[2838..2841] and)
            (NP (DT:[2843..2846] the) (NN:[2847..2850] Ad4)
                (NN:[2851..2858] element)))
          (VP (VBP:[2859..2862] are) (RB:[2863..2866] not)
            (NP-PRD
              (NP (JJ:[2867..2872] major) (NNS:[2873..2883] regulators))
              (PP (IN:[2884..2886] of)
                (NP (JJ:[2887..2894] adrenal) (NN:[2895..2903] hCYP11B2)
                    (NN:[2904..2908] gene) (NN:[2909..2919] expression))))))))
    (.:[2919..2920] .)))

;sentence 20 Span:2922..3022
;Thus far, hCYP11B2 is the first steroid hydroxylase gene which is not
;positively  regulated by SF-1.
;[2932..2940]:cyp450:"hCYP11B2"
;[2954..2973]:substance:"steroid hydroxylase"
;[3017..3021]:substance:"SF-1"
(SENT
  (S
    (ADVP (RB:[2922..2926] Thus) (RB:[2927..2930] far))
    (,:[2930..2931] ,)
    (NP-SBJ (NN:[2932..2940] hCYP11B2))
    (VP (VBZ:[2941..2943] is)
      (NP-PRD
        (NP (DT:[2944..2947] the) (JJ:[2948..2953] first)
          (NML (NN:[2954..2961] steroid) (NN:[2962..2973] hydroxylase))
          (NN:[2974..2978] gene))
        (SBAR
          (WHNP-1 (WDT:[2979..2984] which))
          (S
            (NP-SBJ-1 (-NONE-:[2984..2984] *T*))
            (VP (VBZ:[2985..2987] is) (RB:[2988..2991] not)
              (ADVP (RB:[2992..3002] positively))
              (VP (VBN:[3004..3013] regulated)
                (NP-1 (-NONE-:[3013..3013] *))
                (PP (IN:[3014..3016] by)
                  (NP-LGS (NN:[3017..3021] SF-1)))))))))
    (.:[3021..3022] .)))

;section 21 Span:3026..3071
;PMID: 11932209 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[3026..3030] PMID) (::[3030..3031] :) (CD:[3032..3040] 11932209)
        (-LRB-:[3041..3042] -LSB-) (NNP:[3042..3048] PubMed)
        (HYPH:[3049..3050] -) (NN:[3051..3058] indexed) (IN:[3059..3062] for)
        (NNP:[3063..3070] MEDLINE) (-RRB-:[3070..3071] -RSB-)))
